logo
  

Astellas, Seagen Report Positive Topline Results For Padcev With Keytruda To Treat Urothelial Cancer

Japan's Astellas Pharma Inc. (ALPMY,ALPMY) and Seagen Inc. (SGEN) announced Tuesday positive topline results from the EV-103 trial or Cohort K for Padcev (enfortumab Vedotin-Ejfv) in combination with Merck's Keytruda (pembrolizumab) as a first-line treatment for advanced urothelial cancer.

In pre-market activity on Nasdaq, Seagen shares were gaining around 3.3 percent to trade at $178.50.

The companies said they plan to discuss results with regulatory authorities as they seek to develop a new first-line treatment combination for these patients.

The positive results were reported from the phase 1b/2 EV-103 clinical trial, also known as KEYNOTE-869, Cohort K evaluating PADCEV in combination with Merck's anti-PD-1 therapy KEYTRUDA as first-line treatment in patients with unresectable locally advanced or metastatic urothelial cancer or la/mUC who are ineligible to receive cisplatin-based chemotherapy.

In patients treated with enfortumab vedotin and pembrolizumab, the results overall are generally consistent with previously reported efficacy and safety results of the EV-103 dose-escalation cohort and expansion Cohort A.

Additional Cohort K results will be reported at an upcoming scientific congress.

Astellas, Seagen and Merck are investigating enfortumab vedotin plus pembrolizumab as part of an extensive collaboration, which also includes three Phase 3 studies. The EV-302/KEYNOTE-A39 trial is intended to confirm these results, as well as EV-304/KEYNOTE-B15 and EV-303/KEYNOTE-905 are in muscle-invasive bladder cancer.

In February 2020, the U.S. Food and Drug Administration granted Breakthrough Therapy designation for enfortumab vedotin in combination with pembrolizumab for patients with unresectable la/mUC who are ineligible to receive cisplatin-based chemotherapy in the first-line setting.

For More Such Health News, visit rttnews.com

For comments and feedback contact: editorial@rttnews.com

Follow RTT